Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

Moderna asks investors to wait for full data on flu vaccine amid selloff

Published 12/10/2021, 07:36 AM
Updated 12/10/2021, 04:21 PM
© Reuters. FILE PHOTO: A vial and sryinge are seen in front of a displayed Moderna logo in this illustration taken January 11, 2021. REUTERS/Dado Ruvic

© Reuters. FILE PHOTO: A vial and sryinge are seen in front of a displayed Moderna logo in this illustration taken January 11, 2021. REUTERS/Dado Ruvic

By Leroy Leo and Mrinalika Roy

(Reuters) -Moderna Inc executives called on investors to wait for more data amid a sharp selloff in its shares on Friday, after early data showed its mRNA-based flu vaccine was no better than already approved shots in the market.

The company's shares tumbled 10% after its investor presentation showed antibody levels of its vaccine against all four strains of the influenza virus in an early-stage study were not as robust in older people as Sanofi (NASDAQ:SNY)'s Fluzone HD.

"We can't make a direct comparison. We presented (Fluzone data) only as guidance," a company executive said on a conference call, responding to concerns that Moderna (NASDAQ:MRNA)'s vaccine was inferior to Fluzone HD.

Moderna's vaccine candidate, mRNA-1010, is based on the messenger RNA technology, which also underpins its COVID-19 shots.

Following the huge success of mRNA-based vaccines in fighting the pandemic globally, drugmakers are rushing to tap the technology and develop shots for other diseases, including influenza.

"On one hand, the antibodies increased to good levels, but on the other hand, the levels aren't necessarily seen as high or necessarily better than some high-efficacy vaccines such as Flublok or Fluzone HD," Jefferies (NYSE:JEF) analyst Michael Yee said in a client note.

Moderna executives said the antibody response might have been limited by the population's previous exposure to the flu strains, adding that data on the full immune response, including T-cells, would better measure the effectiveness of the flu vaccines.

"Antibody titers are useful but are not the same as full efficacy," senior executive Jacqueline Miller said.

© Reuters. FILE PHOTO: A vial and sryinge are seen in front of a displayed Moderna logo in this illustration taken January 11, 2021. REUTERS/Dado Ruvic

The early-stage study, testing the vaccine in 180 subjects, is ongoing and a mid-stage study testing it against an already approved flu vaccine is fully enrolled with 500 participants, the company said, adding that the interim analysis is expected in early 2022.

U.S.-listed shares of BioNTech, which along with partner Pfizer Inc (NYSE:PFE) is also developing an mRNA-based influenza vaccine, were down nearly 8%.

Latest comments

They going to fill this vaccine with heavy metals as well? Even Japan refused to administer Modernas covid “vaccine”..
Snake oil salesman.Without the Covid, they got 0...
This company is not tht reliable. From ceo to executives. If the data is not yet completed then why did u release it to public? I guess u dont know what u r doing. Now when the price turns upsidedown, i ask us to wait? lol
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.